Wave Life Sciences LTD Form 4 insider transactions

Wave Life Sciences Director Gregory L. Verdine filed a Form 4 indicating a planned sale of 10,000 ordinary shares on August 22, 2025, under a pre-arranged 10b5-1 trading plan.

Wave Life Sciences Ltd. President and CEO Paul Bolno sold 217,351 ordinary shares for a weighted-average price of $10.098 per share, pursuant to a pre-arranged 10b5-1 trading plan.

A director at Wave Life Sciences Ltd. exercised options and immediately sold 21,000 ordinary shares for a profit of $0.12 per share.

A recent SEC Form 4 filing reveals that Dr. Peter Kolchinsky, a director and managing partner at RA Capital Management, was granted restricted share units and stock options in Wave Life Sciences Ltd. as part of the 2025 Non-Employee Director Compensation Policy.

Wave Life Sciences Director Mark Corrigan was granted 12,700 restricted share units and 76,200 stock options under the 2025 Non-Employee Director Compensation Policy.

Wave Life Sciences director Tan Aik Na acquired 25,400 restricted share units and 152,400 stock options as part of the company's 2025 Non-Employee Director Compensation Policy.

Wave Life Sciences director Ken Takanashi was granted 12,700 restricted share units and options for 76,200 ordinary shares as part of the company's 2025 Non-Employee Director Compensation Policy.

Wave Life Sciences Director Heidi L. Wagner received a grant of 12,700 restricted share units and options for 76,200 ordinary shares.

Wave Life Sciences Director Christian Henry reported acquiring restricted stock units and options, while also selling a portion of his ordinary shares under a pre-arranged trading plan.

Adrian Rawcliffe, a Director at Wave Life Sciences Ltd., was granted restricted share units and stock options as part of the company's 2025 Non-Employee Director Compensation Policy.

Wave Life Sciences Director Gregory L. Verdine received a grant of 12,700 restricted share units and options for 76,200 shares as part of the 2025 Non-Employee Director Compensation Policy.

Wave Life Sciences Director Ken Takanashi sold 4,872 ordinary shares at $8.75 each to cover tax obligations related to restricted share unit vesting.

Wave Life Sciences Director Tan Aik Na sold 1,127 ordinary shares at $8.75 each to cover tax obligations from restricted share unit vesting.

Gregory L. Verdine, a Director at Wave Life Sciences Ltd., sold 30,000 ordinary shares for approximately $6.95 per share on June 13, 2025, as part of a Rule 10b5-1 trading plan.

Christian Henry, a director at Wave Life Sciences, executed option exercises and share sales according to a pre-arranged Rule 10b5-1 trading plan.

Wave Life Sciences CEO Paul Bolno exercised share options and sold shares on March 7, 2025, according to a pre-arranged Rule 10b5-1 trading plan.

Gregory L. Verdine, a director at Wave Life Sciences, exercised stock options to acquire a total of 266,402 ordinary shares.

Chandra Vargeese, Chief Technology Officer of Wave Life Sciences, executed share options and disposed of ordinary shares on March 4, 2025.

Chief Financial Officer Kyle Moran of Wave Life Sciences Ltd. reports the acquisition of restricted share units, ordinary shares, and share options.

Wave Life Sciences CEO Paul Bolno reports the acquisition of 121,000 restricted share units and a grant of options to purchase 1,000,000 ordinary shares.

Chris Francis, SVP at Wave Life Sciences, reports the acquisition of 25,000 restricted share units and options to purchase 151,000 shares.

Chandra Vargeese, Chief Technology Officer of Wave Life Sciences, reports acquisition of restricted share units and share options.

Chandra Vargeese, Chief Technology Officer at Wave Life Sciences, exercised share options and acquired ordinary shares on January 23, 2025.

Wave Life Sciences CEO, Paul Bolno, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Wave Life Sciences CEO, Paul Bolno, sold 51,234 ordinary shares at a weighted average price of $14.32 per share under a pre-arranged 10b5-1 trading plan.

A Wave Life Sciences executive, Chris Francis, exercised stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Chris Francis, SVP at Wave Life Sciences, executed option exercises and sales of ordinary shares under a pre-arranged Rule 10b5-1 trading plan.

Wave Life Sciences CEO Paul Bolno sold 90,474 ordinary shares at $15 per share on October 16, 2024, according to a Form 4 filing with the SEC.

Kyle Moran, CFO of Wave Life Sciences, exercised share options to acquire 25,000 ordinary shares at $2.48 each.

GSK plc reports acquiring additional shares of Wave Life Sciences Ltd., increasing its indirect ownership.